Effectiveness of First‐Line Treatment With Recombinant Interleukin‐1 Receptor Antagonist in Steroid‐Naive Patients With New‐Onset Systemic Juvenile Idiopathic Arthritis: Results of a Prospective Cohort Study
Arthritis & Rheumatology2013Vol. 66(4), pp. 1034–1043
Citations Over TimeTop 1% of 2013 papers
Sebastiaan J. Vastert, Wilco de Jager, Bo Jan Noordman, Dirk Holzinger, Wietse Kuis, Berent J. Prakken, Nico Wulffraat
Abstract
This is the first prospective study in which recombinant IL-1Ra was used as first-line therapy in patients with systemic JIA. We observed excellent responses in nearly all patients within 3 months. In the majority of responding patients, treatment with recombinant IL-1Ra could be stopped within 1 year, with remission being preserved during followup. In approximately one-third of patients, concomitant therapy was required for maintenance of clinical response.
Related Papers
- → The use of interleukin 1 receptor antagonist (anakinra) in Kawasaki disease: A retrospective cases series(2018)126 cited
- → Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature(2018)119 cited
- → Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe COVID-19: A case report(2020)46 cited
- → Anakinra in Still’s disease: a profile of its use(2018)23 cited
- → Anakinra‐Induced Acute Liver Failure in an Adolescent Patient with Still's Disease(2016)24 cited